Skip Navigation


International Immunology Advance Access originally published online on June 13, 2006
International Immunology 2006 18(8):1279-1283; doi:10.1093/intimm/dxl059
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
18/8/1279    most recent
dxl059v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Nagaraj, S
Right arrow Articles by Schmidt-Wolf, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nagaraj, S
Right arrow Articles by Schmidt-Wolf, I.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Japanese Society for Immunology. 2006. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

Dendritic cells pulsed with alpha-galactosylceramide induce anti-tumor immunity against pancreatic cancer in vivo

S Nagaraj1,2,*, C Ziske1,*, J Strehl1, D Messmer3, T Sauerbruch1 and IGH Schmidt-Wolf1

1 Department of Internal Medicine I, Rheinische Friedrich-Wilhelms-Universität, Sigmund Freud Strasse 25, 53105 Bonn, Germany
2 H. Lee Moffitt Cancer Center, University of South Florida, MRC-2 E, Room 2068, 12902 Magnolia Dr., Tampa, FL 33612, USA
3 Department of Medicine, John and Rebecca Moores Cancer Center, University of California San Diego, La Jolla, CA 92093-0663, USA

Correspondence to: I. G. H. Schmidt-Wolf; E-mail: ingo.schmidt-wolf{at}ukb.uni-bonn.de

Ductal pancreatic adenocarcinoma is the fourth leading cause of cancer death in the Western world. Unfortunately, recent advances in diagnostics, staging and therapy have not resulted in significant improvements. Thus, new approaches are necessary to improve the outcome of patients with exocrine pancreatic cancer. We tested triggering of specific T lymphocytes in vivo by using the immunocompetent mouse strain C57BL/6. In the present study, we tried to enhance the anti-tumor effect against pancreatic carcinoma by supplementary triggering of NKT cells in vivo. We challenged Panc02 tumor-bearing mice by intratumoral vaccination with alpha-galactosylceramide (alpha-GalCer)-loaded dendritic cells (DCs). A significant expansion of IFN{gamma}-producing NKT cells was observed which also correlated with decrease in tumor growth in vivo. Hence, DCs loaded with alpha-GalCer could lead to a novel treatment option for patients with pancreatic cancer.

Keywords: alpha-galactosylceramide, dendritic cells, NKT cells, pancreatic cancer

* These authors contributed equally to this study.

Transmitting editor: S. M. Hedrick


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.